⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma

Official Title: An Open-label, Single-arm, Phase 2 Study of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma

Study ID: NCT00511238

Study Description

Brief Summary: To evaluate the overall response rate and safety and tolerability of carfilzomib in subjects with relapsed and refractory multiple myeloma. Patients must have received prior treatment with bortezomib and either thalidomide or lenalidomide and be refractory to their last treatment.

Detailed Description:

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Southern Cancer Center, Mobile, Alabama, United States

Mayo Clinic Scottsdale, Scottsdale, Arizona, United States

Tower Cancer Research Foundation, Beverly Hills, California, United States

City of Hope National Medical Center, Duarte, California, United States

Scripps Clinic, La Jolla, California, United States

University of California, San Francisco, San Francisco, California, United States

Florida Cancer Specialists, Fort Myers, Florida, United States

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Emory University Winship Cancer Institute, Atlanta, Georgia, United States

Northwestern Universtiy, Chicago, Illinois, United States

Rush University Medical Center, Chicago, Illinois, United States

University of Kentucky, Lexington, Kentucky, United States

University of Michigan, Ann Arbor, Michigan, United States

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Mayo Clinic - Rochester, Rochester, Minnesota, United States

Washington University School of Medicine, Saint Louis, Missouri, United States

Hackensack University Medical Center, Hackensack, New Jersey, United States

Roswell Park Cancer Institute, Buffalo, New York, United States

St. Vincent Catholic Medical Center, New York, New York, United States

Wake Forest University, Winston-Salem, North Carolina, United States

Gabrail Cancer Center, Canton, Ohio, United States

Oncology & Hematology Care, Cincinnati, Ohio, United States

Cleveland Clinic, Cleveland, Ohio, United States

University of Pennsylvania, Philadelphia, Pennsylvania, United States

Sarah Cannon Research Institute, Nashville, Tennessee, United States

MD Anderson Cancer Center, Houston, Texas, United States

Northwest Cancer Center, Houston, Texas, United States

University of Utah, Salt Lake City, Utah, United States

University of Calgary, Calgary, Alberta, Canada

University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada

Leukemia/BMT Program of BC, Vancouver, British Columbia, Canada

Princess Margaret Hospital, Toronto, Ontario, Canada

Royal Victoria Hospital, Montreal, Quebec, Canada

Jewish General Hospital, Montreal, Quebec, Canada

Contact Details

Name: MD

Affiliation: Amgen

Role: STUDY_DIRECTOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: